Cell Biotech Co (049960) Fair Value & Analysis
Healthcare · KR · Market cap 105B KRW
Fair value as of: Jul 20, 2026
From 23 valuation models · updated 20 days ago
Share price +3.3% over the past month.
A solid business, screening 25% undervalued on our models.
What matters now
- Solid quality (67/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (13,994 KRW to 26,133 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 9,031 KRW – 18,110 KRW · fair‑value band 13,994 KRW – 26,133 KRW · the 15,560 KRW price screens below the 19,433 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Cell Biotech Co (049960) currently trades at 15,560 KRW, while our model-based Fair Value estimate is 19,433 KRW, implying the stock looks roughly 24.9% undervalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Cell Biotech Co generated revenue of 48.8B KRW at a net margin of 30.0%. Revenue declined 2.6% year over year. Fundamentals as of Jul 20, 2026
Our scenario range runs from 13,994 KRW (bear case) to 26,133 KRW (bull case); at 15,560 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 16% below its 52-week high and 42% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 25%, 049960 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Growth Earnings (22,949 KRW) versus Earnings-Based (11,153 KRW). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 55
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd.
Full company description
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cell Biotech Co reported revenue of 53.1B KRW in FY2025 versus 46.9B KRW in FY2021, a compound +3.2%/yr. Reported net income was 10.1B KRW in FY2025, compounding −0.6%/yr from FY2021.
Watch 049960: get an alert when its fair value changes →
Peer Group
Health Care · 2228 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)
Valuation Multiples vs Health Care median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| MEDIPOST Co 078160 | 8,150 KRW | 4,269 KRW | -48% |
| Bioneer Corporation 064550 | 6,020 KRW | 8,312 KRW | +38% |
| Macrogen, Inc 038290 | 11,090 KRW | 4,457 KRW | -60% |
| Panagene Inc 046210 | 1,068 KRW | 480.36 KRW | -55% |
| Biotoxtech Co 086040 | 2,010 KRW | 1,481 KRW | -26% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
| GSK plc GSKN | 917.00 MXN | 1,078 MXN | +18% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
Compare Cell Biotech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cell Biotech Co (049960) overvalued or undervalued?
What is the fair value of 049960?
What is the quality score of 049960?
What is the revenue of Cell Biotech Co (049960)?
What is the net profit margin of 049960?
Does Cell Biotech Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cell Biotech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.